Sparrow Pharmaceuticals to Present on HSD-1 InhibitorHSD-1 Inhibitor Clofutriben (SPI-62) for Polymyalgia Rheumatica at the European Congress of Rheumatology 2024
06 Jun 2024
Phase 2Clinical Result
Presentation will describe how clofutriben modulates key biomarkers of prednisolone efficacy and toxicity in patients with polymyalgia rheumatica.
Sparrow’s Chief Scientific Officer will describe new insights about glucocorticoid action on the 75th anniversary of glucocorticoid utilization for treatment of rheumatic diseases.
PORTLAND, Ore.--(BUSINESS WIRE)-- Sparrow Pharmaceuticals will present interim results from a Phase 2 clinical trial of its novel HSD-1 inhibitorHSD-1 inhibitor, clofutriben (SPI-62), administered in combination with prednisolone to patients with polymyalgia rheumatica, at the European Congress of Rheumatology (EULAR) 2024 congress in Vienna, Austria during a highlighted session, “The 75th Anniversary of Glucocorticoids - what have we learnt?”
Sparrow’s Founder and Chief Scientific Officer will describe how clofutriben modulates key biomarkers of prednisolone efficacy and toxicity in his presentation, "The 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 Differentially Modulates Prednisolone Immune and Musculoskeletal Efficacy and Bone Formation/Resorption Biomarkers in Patients with Polymyalgia Rheumatica (PMR): An Interim Report.”
Presenter: Dr. David Katz, Ph.D., Chief Scientific Officer, Sparrow Pharmaceuticals
Session Location: Room C7
Session Time: 15 June 2024 at 12:50 CEDT
To learn more about Sparrow Pharmaceuticals clofutriben, visit .
About Sparrow Pharmaceuticals
Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into glucocorticoid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, clofutriben (SPI-62), is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular glucocorticoids in key tissues.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.